Related Experiment Videos
[Broncaspin in respiratory diseases in pediatrics. Clinical contribution]
Insights
Broncaspin (guacetisal) effectively treated pediatric airway inflammation and cough in 42 children. This rectal preparation showed rapid action and good tolerance with no significant side effects.
Area of Science:
- Pediatric Pulmonology
- Pharmacology
- Clinical Therapeutics
Background:
- Inflammatory diseases of the upper and lower airways are common in children.
- Bronchospasm frequently complicates pediatric airway inflammatory conditions.
- Effective and safe treatment options for acute pediatric respiratory illnesses are needed.
Purpose of the Study:
- To evaluate the efficacy and safety of Broncaspin (guacetisal) in children with inflammatory airway diseases.
- To assess the antipyretic and anti-cough effects of rectally administered Broncaspin.
- To determine the local and systemic tolerance of Broncaspin in pediatric patients.
Main Methods:
- Rectal administration of Broncaspin (guacetisal) to 42 children.
- Dosage adjusted based on age: 1-2 suppositories of 0.5 g/day for children up to six years, and 2 suppositories/day for those older than six.
- Clinical observation of antipyretic, anti-cough effects, and side effects.
Main Results:
- Broncaspin demonstrated a good antipyretic and anti-cough effect in the majority of cases.
- The preparation exhibited rapid onset of action.
- Excellent local and general tolerance was observed, with no reported haematological, hepatic, or renal side effects.
Conclusions:
- Broncaspin (guacetisal) is a valuable therapeutic agent for managing acute inflammatory airway diseases in children.
- Its efficacy, rapid action, and favorable safety profile make it suitable for pediatric use.
- Broncaspin offers a promising option for anti-inflammatory and anti-cough treatment in infants and young children.
Abstract:
Broncaspin (guacetisal) has been administered rectally to 42 children suffering from inflammatory diseases of the upper and lower airways, most cases being complicated by bronchospasm. Treatment involving a dose of 1-2 suppositories of 0.5 g/die up to six years of age, and 2 suppositories/die after the sixth year always produced a good antipyretic and anti-cough effect. The preparation was outstanding for speed of action, local and general tolerance, and the absence of haematological, hepatic or renal side-effects. The new drug is considered to be a valuable instrument for anti-inflammatory and anti-cough treatment in acute diseases of the airways in infancy.